Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

Attenuation of immune-mediated bone marrow damage in conventionally housed mice.

Li J, Dubois W, Thovarai V, Wu Z, Feng X, Peat T, Zhang S, Sen SK, Trinchieri G, Chen J, Mock BA, Young NS.

Mol Carcinog. 2020 Feb;59(2):237-245. doi: 10.1002/mc.23151. Epub 2020 Jan 2.

PMID:
31898340
2.

The transcription factor MZF1 differentially regulates murine Mtor promoter variants linked to tumor susceptibility.

Zhang S, Shi W, Ramsay ES, Bliskovsky V, Eiden AM, Connors D, Steinsaltz M, DuBois W, Mock BA.

J Biol Chem. 2019 Nov 8;294(45):16756-16764. doi: 10.1074/jbc.RA119.009779. Epub 2019 Sep 23.

PMID:
31548308
3.

The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription.

Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, Lee M, Mock BA, Yuspa SH, Larson D, Wakefield LM, Huang J.

Nat Commun. 2019 May 6;10(1):2071. doi: 10.1038/s41467-019-10102-6.

4.

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex.

Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, Hewitt WM, Alden S, Hilimire TA, He F, Michalowski AM, Simmons JK, Saunders LB, Zhang S, Connors D, Walters KJ, Mock BA, Schneekloth JS Jr.

Nat Commun. 2018 Oct 12;9(1):4229. doi: 10.1038/s41467-018-06315-w.

5.

Characterization of clinically used oral antiseptics as quadruplex-binding ligands.

Calabrese DR, Zlotkowski K, Alden S, Hewitt WM, Connelly CM, Wilson RM, Gaikwad S, Chen L, Guha R, Thomas CJ, Mock BA, Schneekloth JS Jr.

Nucleic Acids Res. 2018 Apr 6;46(6):2722-2732. doi: 10.1093/nar/gky084.

6.

The Reign of Antibodies: A Celebration of and Tribute to Michael Potter and His Homogeneous Immunoglobulin Workshops.

Gearhart PJ, Mock BA, Casellas R, Cancro MP.

J Immunol. 2018 Jan 1;200(1):23-26. doi: 10.4049/jimmunol.1701516. No abstract available.

7.

mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.

Sintes J, Gentile M, Zhang S, Garcia-Carmona Y, Magri G, Cassis L, Segura-Garzón D, Ciociola A, Grasset EK, Bascones S, Comerma L, Pybus M, Lligé D, Puga I, Gutzeit C, He B, DuBois W, Crespo M, Pascual J, Mensa A, Aróstegui JI, Juan M, Yagüe J, Serrano S, Lloreta J, Meffre E, Hahne M, Cunningham-Rundles C, Mock BA, Cerutti A.

Nat Commun. 2017 Nov 13;8(1):1462. doi: 10.1038/s41467-017-01602-4.

8.

cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma.

He Y, Zhu W, Shin MH, Gary J, Liu C, Dubois W, Hoover SB, Jiang S, Marrogi E, Mock B, Simpson RM, Huang J.

Stem Cell Reports. 2017 Jun 6;8(6):1630-1644. doi: 10.1016/j.stemcr.2017.04.029. Epub 2017 May 25.

9.

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.

Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, Zhang K, Gary J, Zhang S, Gaikwad S, Connors D, Watson N, Leon E, Chen JQ, Kuehl WM, Lee MP, Zingone A, Landgren O, Ordentlich P, Huang J, Mock BA.

Mol Cancer Ther. 2017 Sep;16(9):2008-2021. doi: 10.1158/1535-7163.MCT-17-0171. Epub 2017 May 18.

10.

Differential effects of Cdh23(753A) on auditory and vestibular functional aging in C57BL/6J mice.

Mock BE, Vijayakumar S, Pierce J, Jones TA, Jones SM.

Neurobiol Aging. 2016 Jul;43:13-22. doi: 10.1016/j.neurobiolaging.2016.03.013. Epub 2016 Mar 26.

11.

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy.

Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA.

Clin Cancer Res. 2016 Jan 15;22(2):277-83. doi: 10.1158/1078-0432.CCR-14-3239. Epub 2015 Nov 25. Review.

12.

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression.

Felsenstein KM, Saunders LB, Simmons JK, Leon E, Calabrese DR, Zhang S, Michalowski A, Gareiss P, Mock BA, Schneekloth JS Jr.

ACS Chem Biol. 2016 Jan 15;11(1):139-48. doi: 10.1021/acschembio.5b00577. Epub 2015 Nov 6.

13.

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.

Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ.

Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1.

14.

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.

Mol Oncol. 2014 Mar;8(2):261-72. doi: 10.1016/j.molonc.2013.11.007. Epub 2013 Dec 3.

15.

Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression.

Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T.

Cell Rep. 2013 Sep 12;4(5):913-20. doi: 10.1016/j.celrep.2013.07.030. Epub 2013 Aug 29.

16.

B cell-specific deficiencies in mTOR limit humoral immune responses.

Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.

J Immunol. 2013 Aug 15;191(4):1692-703. doi: 10.4049/jimmunol.1201767. Epub 2013 Jul 15.

17.

Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.

Boone BA, Zeh HJ, Mock BK, Johnson PJ, Dvorchik I, Lee K, Moser AJ, Bartlett DL, Marsh JW.

HPB (Oxford). 2014 Mar;16(3):197-203. doi: 10.1111/hpb.12119. Epub 2013 Apr 22.

18.

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses.

Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.

J Immunol Methods. 2013 Apr 30;390(1-2):52-62. doi: 10.1016/j.jim.2013.01.008. Epub 2013 Jan 25.

19.

Striatal D(2)/D(3) receptor availability is inversely correlated with cannabis consumption in chronic marijuana users.

Albrecht DS, Skosnik PD, Vollmer JM, Brumbaugh MS, Perry KM, Mock BH, Zheng QH, Federici LA, Patton EA, Herring CM, Yoder KK.

Drug Alcohol Depend. 2013 Feb 1;128(1-2):52-7. doi: 10.1016/j.drugalcdep.2012.07.016. Epub 2012 Aug 19.

20.

Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study.

Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A.

Hepatology. 2012 Dec;56(6):2221-30. doi: 10.1002/hep.25935. Epub 2012 Oct 14.

PMID:
22767263
21.

Mouse genetics 2011: meeting report.

Simmons JK, Amlin-Van Schaick JC, Geiger TR, Reilly K, Hunter K, Mock BA.

Mamm Genome. 2012 Apr;23(3-4):225-31. doi: 10.1007/s00335-012-9390-6. Epub 2012 Feb 23. No abstract available.

22.

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

Smrz D, Kim MS, Zhang S, Mock BA, Smrzová S, DuBois W, Simakova O, Maric I, Wilson TM, Metcalfe DD, Gilfillan AM.

Blood. 2011 Dec 22;118(26):6803-13. doi: 10.1182/blood-2011-06-359984. Epub 2011 Nov 3.

23.

Reliability of striatal [¹¹C]raclopride binding in smokers wearing transdermal nicotine patches.

Yoder KK, Albrecht DS, Kareken DA, Federici LM, Perry KM, Patton EA, Zheng QH, Mock BH, O'Connor SJ, Herring CM.

Eur J Nucl Med Mol Imaging. 2012 Feb;39(2):220-5. doi: 10.1007/s00259-011-1965-z. Epub 2011 Oct 19.

24.

An automated SPE-based high-yield synthesis of [11C]acetate and [11C]palmitate: no liquid-liquid extraction, solvent evaporation or distillation required.

Mock BH, Brown-Proctor C, Green MA, Steele B, Glick-Wilson BE, Zheng QH.

Nucl Med Biol. 2011 Nov;38(8):1135-42. doi: 10.1016/j.nucmedbio.2011.05.007. Epub 2011 Aug 9.

PMID:
21831651
25.

CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.

Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ.

Cell Death Differ. 2011 Jul;18(7):1174-83. doi: 10.1038/cdd.2010.187. Epub 2011 Jan 21.

26.

Assessment of i.p. injection of [18F]fallypride for behavioral neuroimaging in rats.

Yoder KK, Mock BH, Zheng QH, McCarthy BP, Riley AA, Hutchins GD.

J Neurosci Methods. 2011 Mar 15;196(1):70-5. doi: 10.1016/j.jneumeth.2010.12.027. Epub 2011 Jan 8.

PMID:
21219928
27.

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production.

Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.

Blood. 2011 Jan 27;117(4):1228-38. doi: 10.1182/blood-2010-05-287821. Epub 2010 Nov 15.

28.

Gravity receptor aging in the CBA/CaJ strain: a comparison to auditory aging.

Mock B, Jones TA, Jones SM.

J Assoc Res Otolaryngol. 2011 Apr;12(2):173-83. doi: 10.1007/s10162-010-0247-y. Epub 2010 Nov 5.

29.

Test-retest variability of [¹¹C]raclopride-binding potential in nontreatment-seeking alcoholics.

Yoder KK, Albrecht DS, Kareken DA, Federici LM, Perry KM, Patton EA, Zheng QH, Mock BH, O'Connor S, Herring CM.

Synapse. 2011 Jul;65(7):553-61. doi: 10.1002/syn.20874. Epub 2010 Dec 8.

30.

An improved synthesis of dopamine D2/D3 receptor radioligands [11C]fallypride and [18F]fallypride.

Gao M, Wang M, Mock BH, Glick-Wilson BE, Yoder KK, Hutchins GD, Zheng QH.

Appl Radiat Isot. 2010 Jun;68(6):1079-86. doi: 10.1016/j.apradiso.2009.09.071. Epub 2010 Jan 25.

PMID:
20167502
31.

Fully automated synthesis and initial PET evaluation of [11C]PBR28.

Wang M, Yoder KK, Gao M, Mock BH, Xu XM, Saykin AJ, Hutchins GD, Zheng QH.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5636-9. doi: 10.1016/j.bmcl.2009.08.051. Epub 2009 Aug 15.

32.

Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility.

Zhang K, Kagan D, DuBois W, Robinson R, Bliskovsky V, Vass WC, Zhang S, Mock BA.

Blood. 2009 Oct 1;114(14):2952-60. doi: 10.1182/blood-2009-01-198812. Epub 2009 Aug 4.

33.

Developmental differences in learning and error processing: evidence from ERPs.

Eppinger B, Mock B, Kray J.

Psychophysiology. 2009 Sep;46(5):1043-53. doi: 10.1111/j.1469-8986.2009.00838.x. Epub 2009 May 28.

PMID:
19497006
34.

Dopamine transporter binding in rat striatum: a comparison of [O-methyl-11C]beta-CFT and [N-methyl-11C]beta-CFT.

Yoder KK, Hutchins GD, Mock BH, Fei X, Winkle WL, Gitter BD, Territo PR, Zheng QH.

Nucl Med Biol. 2009 Jan;36(1):11-6. doi: 10.1016/j.nucmedbio.2008.10.007.

PMID:
19181264
35.

Synthesis of new carbon-11 labeled cyclofenil derivatives for PET imaging of breast cancer estrogen receptors.

Gao M, Wang M, Mock BH, Miller KD, Sledge GW, Hutchins GD, Zheng QH.

Appl Radiat Isot. 2008 Apr;66(4):523-9. Epub 2007 Nov 19.

PMID:
18155914
36.

Better or worse than expected? Aging, learning, and the ERN.

Eppinger B, Kray J, Mock B, Mecklinger A.

Neuropsychologia. 2008 Jan 31;46(2):521-39. Epub 2007 Sep 7.

PMID:
17936313
37.

Partial k-space reconstruction in single-shot diffusion-weighted echo-planar imaging.

Storey P, Frigo FJ, Hinks RS, Mock BJ, Collick BD, Baker N, Marmurek J, Graham SJ.

Magn Reson Med. 2007 Mar;57(3):614-9.

38.

Synthesis and biodistribution of new radiolabeled high-affinity choline transporter inhibitors [11C]hemicholinium-3 and [18F]hemicholinium-3.

Zheng QH, Gao M, Mock BH, Wang S, Hara T, Nazih R, Miller MA, Receveur TJ, Lopshire JC, Groh WJ, Zipes DP, Hutchins GD, DeGrado TR.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2220-4. Epub 2007 Feb 4.

PMID:
17303422
39.

Evaluation of [11C]hemicholinium-15 and [18F]hemicholinium-15 as new potential PET tracers for the high-affinity choline uptake system in the heart.

Gao M, Miller MA, DeGrado TR, Mock BH, Lopshire JC, Rosenberger JG, Dusa C, Das MK, Groh WJ, Zipes DP, Hutchins GD, Zheng QH.

Bioorg Med Chem. 2007 Feb 1;15(3):1289-97. Epub 2006 Nov 10.

PMID:
17116396
40.

Synthesis of carbon-11 labeled fluorinated 2-arylbenzothiazoles as novel potential PET cancer imaging agents.

Wang M, Gao M, Mock BH, Miller KD, Sledge GW, Hutchins GD, Zheng QH.

Bioorg Med Chem. 2006 Dec 15;14(24):8599-607. Epub 2006 Sep 8.

PMID:
16962783
41.

A physiologic imaging pilot study of breast cancer treated with AZD2171.

Miller KD, Miller M, Mehrotra S, Agarwal B, Mock BH, Zheng QH, Badve S, Hutchins GD, Sledge GW Jr.

Clin Cancer Res. 2006 Jan 1;12(1):281-8.

42.

ntPET: a new application of PET imaging for characterizing the kinetics of endogenous neurotransmitter release.

Morris ED, Yoder KK, Wang C, Normandin MD, Zheng QH, Mock B, Muzic RF Jr, Froehlich JC.

Mol Imaging. 2005 Oct-Dec;4(4):473-89.

PMID:
16285909
43.

Interferon-alphacon-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose.

Kroegel C, Bergmann N, Foerster M, Workalemahu G, Machnik A, Mock B, Reissig A.

Respiration. 2006;73(4):566-70. Epub 2005 Sep 29.

PMID:
16195656
44.

Facile synthesis and PET imaging of a novel potential heart acetylcholinesterase tracer N-[11C]methyl-3-[[(dimethylamino)carbonyl]oxy]-2-(2',2'-diphenylpropionoxymethyl)pyridinium.

Wang JQ, Miller MA, Mock BH, Lopshire JC, Groh WJ, Zipes DP, Hutchins GD, Zheng QH.

Bioorg Med Chem Lett. 2005 Oct 15;15(20):4510-4.

PMID:
16112863
45.
46.

A facile synthesis of [(11)C]acetylene.

Nazih R, Blauser JP, Mock BH, Degrado TR.

Appl Radiat Isot. 2005 Sep;63(3):305-9.

PMID:
15990324
48.

Dopamine D(2) receptor availability is associated with subjective responses to alcohol.

Yoder KK, Kareken DA, Seyoum RA, O'connor SJ, Wang C, Zheng QH, Mock B, Morris ED.

Alcohol Clin Exp Res. 2005 Jun;29(6):965-70.

PMID:
15976522
49.
50.

Interferon-gamma-1b: therapeutic option in advanced idiopathic pulmonary fibrosis?

Kroegel C, Mock B, Hengst U, Reissig A.

Respiration. 2004 Nov-Dec;71(6):656-7. No abstract available.

PMID:
15627882

Supplemental Content

Support Center